Exome Asset Management LLC: BRIDGEBIO PHARMA INC (BBIO): Quarterly 13F Position History
As of Q1 2026, Exome Asset Management LLC reported 67,492 shares of BRIDGEBIO PHARMA INC (BBIO), worth $5.0M and representing 2.9% of its 13F equity book. Quarter-over-quarter share count change: 13,231 (-16.4%) . The position first appeared in Q4 2023 and has been disclosed across 10 13F-HR filings in Pactolio's tracked window.
- 67,492Shares Held (Latest Filing)
- $5.0MReported Market Value (Latest Filing)
- 2.9%Portfolio Weight (% of 13F Equity Book)
- 13,231Quarter-over-Quarter Share Change
- -$1.2MQuarter-over-Quarter Value Change
- 246,700Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 10 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 67,492 | 13,231 | -16.4% | $5.0M | 2.9% | $74.3 |
| Q4 2025 | 80,723 | 52,364 | -39.3% | $6.2M | 3.1% | $76.5 |
| Q3 2025 | 133,087 | 22,446 | -14.4% | $6.9M | 4.6% | $51.9 |
| Q2 2025 | 155,533 | 9,963 | -6.0% | $6.7M | 5.5% | $43.2 |
| Q1 2025 | 165,496 | 81,204 | -32.9% | $5.7M | 5.1% | $34.6 |
| Q4 2024 | 246,700 | +35,700 | +16.9% | $6.8M | 5.1% | $27.4 |
| Q3 2024 | 211,000 | +132,093 | +167.4% | $5.4M | 3.7% | $25.5 |
| Q2 2024 | 78,907 | +30,100 | +61.7% | $2.0M | 1.7% | $25.3 |
| Q1 2024 | 48,807 | 16,306 | -25.0% | $1.5M | 1.3% | $30.9 |
| Q4 2023 | 65,113 | — | — | $2.6M | 2.6% | $40.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Exome Asset Management LLC first disclose a BBIO position in 13F-HR filings?
Exome Asset Management LLC first reported BRIDGEBIO PHARMA INC (BBIO) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 10 reported quarters within Pactolio's tracked window.
What was Exome Asset Management LLC's most recent quarter-over-quarter share-count change in BBIO?
Between Q4 2025 and Q1 2026, Exome Asset Management LLC reduced its BBIO position by 13,231 shares (-16.4%), leaving 67,492 shares at a market value of $5.0M.
Does the implied price-per-share represent Exome Asset Management LLC's cost basis in BBIO?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.